- Sterling Pharma Solutions has appointed Karl Rotthier as Chief Executive Officer, effective 21 October 2025, succeeding retiring CEO Kevin Cook.
- Rotthier will oversee the company’s global operations and continue investment in its antibody-drug conjugate business.
Sterling Pharma Solutions, a global CDMO, has announced the appointment of Karl Rotthier as its new Chief Executive Officer, effective 21 October 2025. Rotthier succeeds Kevin Cook, who has led the company since 2013 and will support the transition until 31 October 2025.
“We are delighted to welcome Karl to Sterling Pharma Solutions. Karl is a highly experienced CEO who has worked in both listed and private CDMO companies in Europe and globally. He has leadership experience working in fast-growing businesses that have expanded internationally and has a strong track record of driving commercial effectiveness and operational excellence.”
Chris Brinsmead CBE, Chair of the Sterling Board
Rotthier will lead Sterling’s global operations, focusing on commercial growth, operational efficiency, and strategic investment, including its antibody-drug conjugate (ADC) business. He commented, “It is a privilege to join Sterling at an important time in the company’s growth and development. I am delighted to now have the opportunity to lead the business and leverage the market opportunities in Europe and the US, as well as to continue to invest in our antibody-drug conjugate business, ultimately to help bring critical therapies to patients worldwide.”
Sterling’s investors, GHO and Partners Group, also acknowledged Kevin Cook’s contribution, highlighting the transformation of the company from a single UK site into a multi-site global CDMO with a customer-centric, quality-focused culture.
